Provided by Tiger Fintech (Singapore) Pte. Ltd.

Viatris Inc.

8.98
-0.2600-2.81%
Post-market: 9.020.0407+0.45%19:48 EDT
Volume:17.47M
Turnover:158.49M
Market Cap:10.72B
PE:-16.90
High:9.36
Open:9.27
Low:8.95
Close:9.24
Loading ...

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Zacks
·
06 Nov 2024

Viatris Keeps Quarterly Dividend at $0.12 per Share, Payable Dec. 13 to Shareholders of Record on Nov. 22

MT Newswires Live
·
06 Nov 2024

Viatris declares $0.12 dividend

seekingalpha
·
05 Nov 2024

Viatris to Report Q3 Earnings: What's in the Cards?

Zacks
·
05 Nov 2024

Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics

Zacks
·
04 Nov 2024

Idorsia announces financial results for the first nine months of 2024

GlobeNewswire
·
29 Oct 2024

Lexicon Pharmaceuticals to Get $25 Million From Viatris in Global Sotagliflozin Licensing Deal

MT Newswires Live
·
17 Oct 2024

Lexicon receives $25M upfront from Viatris for exclusive sotagliflozin license

TIPRANKS
·
17 Oct 2024

BRIEF-Viatris Announces Exclusive Licensing Agreement With Lexicon Pharmaceuticals For Sotagliflozin In All Markets Outside Of The U.S. And Europe

Reuters
·
17 Oct 2024

Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe

THOMSON REUTERS
·
17 Oct 2024

Viatris Inc - to Pay $25 Million Upfront for Sotagliflozin Rights

THOMSON REUTERS
·
17 Oct 2024

Strength Seen in Cencora (COR): Can Its 3.7% Jump Turn into More Strength?

Zacks
·
16 Oct 2024

Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments

Insider Monkey
·
12 Oct 2024

Viatris 2023 Sustainability Report: Reducing Packaging Material

ACCESSWIRE
·
10 Oct 2024

Viatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations

GuruFocus.com
·
10 Oct 2024

BUZZ-Viatris' anxiety disorder drug meets main goal in late-stage trial; shares up

Reuters
·
09 Oct 2024